Rethinking the value of survival: clinical trials should measure patient preferences for survival on entry to trials

Journal of Clinical Epidemiology

Volumn 77, Issue , 2016, Pages 137-138

  Doctor, Jason N ^a   Huesch, Marco D ^a   Meeker, Daniella ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CANCER THERAPY; CLINICAL TRIAL (TOPIC); FEMALE; HUMAN; LETTER; LIFE EXTENSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT PREFERENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL; ADOLESCENT; ATTITUDE TO HEALTH; MIDDLE AGED; PSYCHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ATTITUDE TO HEALTH; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT PREFERENCE; SURVIVAL; YOUNG ADULT;

EID: 84994553123     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2016.03.030     Document Type: Letter

References (5)

1. [1] Temel, J., Greer, J.A., Muzikansky, A., Gallagher, E.R., Admane, S., Jackson, V.A., et al. Early palliative care for patients with metastatic non–small-cell lung cancer. New Engl J Med 363 (2010), 733–742.
2. [2] Fojo, T., Mailankody, S., Lo, A., Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity. JAMA Otolaryngol Head Neck Surg 140 (2014), 1225–1236.
3. [3] Miyamoto, J.M., Eraker, S.A., Parametric models of the utility of survival duration: tests of axioms in a generic utility framework. Organ Behav Hum Decis Process 44 (1989), 166–202.
4. [4] van Osch, S.M., van den Hout, W.B., Stiggelbout, A.M., Exploring the reference point in prospect theory: gambles for length of life. Med Decis Making 26 (2006), 338–346.
5. [5] Verhoef, L.C., de Haan, A.F., van Daal, W.A., Risk attitude in gambles with years of life empirical support for prospect theory. Med Decis Making 14 (1994), 194–200.